Patent controversies and court cases Cancer diagnosis, therapy and prevention

被引:4
作者
Fialho, Arsenio M. [2 ]
Chakrabarty, Ananda M. [1 ]
机构
[1] Univ Illinois, Coll Med, Dept Microbiol & Immunol, Chicago, IL 60612 USA
[2] Inst Super Tecn, Inst Biotechnol & Bioengn, Dept Bioengn, Lisbon, Portugal
关键词
anticancer drugs; breast/ovarian cancer; cancer diagnosis; human genes/mutations; legal conflicts; patents; CUPREDOXIN AZURIN; REGRESSION; MODEL;
D O I
10.4161/cbt.21958
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Patents are issued essentially by all countries on inventions that are deemed novel, non-obvious, clearly described and of significant utility or industrial application. The only exceptions to patenting an invention are abstract ideas, laws of nature and natural phenomena, although the exceptions vary depending on countries where moral, public order or human rights considerations are also taken into account. Although patent laws are updated over decades, the rapid progress of science creates situations that the patent laws on the book cannot address, leading to contentious legal issues. This is often true for life saving drugs, particularly drugs for cancers or HIV/AIDS, which are expensive and beyond the reach of poor people because of the proprietary positions of these patented drugs. Another contentious issue is the patent eligibility of human genes and mutations that are often thought of nature's contribution to human health and propagation and should be beyond the reach of patentability. In this review, we address some of these current legal issues and their implications for the development of diagnostic methods, therapeutic interventions and even prevention for cancer, a scourge of mankind.
引用
收藏
页码:1229 / 1234
页数:6
相关论文
共 23 条
[1]
Overcoming drug resistance in multi-drug resistant cancers and microorganisms A conceptual framework [J].
Avner, Benjamin S. ;
Fialho, Arsenio M. ;
Chakrabarty, Ananda M. .
BIOENGINEERED, 2012, 3 (05) :262-270
[2]
Integrated genomic analyses of ovarian carcinoma [J].
Bell, D. ;
Berchuck, A. ;
Birrer, M. ;
Chien, J. ;
Cramer, D. W. ;
Dao, F. ;
Dhir, R. ;
DiSaia, P. ;
Gabra, H. ;
Glenn, P. ;
Godwin, A. K. ;
Gross, J. ;
Hartmann, L. ;
Huang, M. ;
Huntsman, D. G. ;
Iacocca, M. ;
Imielinski, M. ;
Kalloger, S. ;
Karlan, B. Y. ;
Levine, D. A. ;
Mills, G. B. ;
Morrison, C. ;
Mutch, D. ;
Olvera, N. ;
Orsulic, S. ;
Park, K. ;
Petrelli, N. ;
Rabeno, B. ;
Rader, J. S. ;
Sikic, B. I. ;
Smith-McCune, K. ;
Sood, A. K. ;
Bowtell, D. ;
Penny, R. ;
Testa, J. R. ;
Chang, K. ;
Dinh, H. H. ;
Drummond, J. A. ;
Fowler, G. ;
Gunaratne, P. ;
Hawes, A. C. ;
Kovar, C. L. ;
Lewis, L. R. ;
Morgan, M. B. ;
Newsham, I. F. ;
Santibanez, J. ;
Reid, J. G. ;
Trevino, L. R. ;
Wu, Y. -Q. ;
Wang, M. .
NATURE, 2011, 474 (7353) :609-615
[3]
Chakrabarty A. M., 2012, J COMMER BIOTECHNOL, V18, P4
[4]
Chakrabarty Ananda M, 2010, Bioeng Bugs, V1, P2, DOI 10.4161/bbug.1.1.9850
[5]
Cupredoxin-cancer interrelationship: Azurin binding with EphB2, interference in EphB2 tyrosine phosphorylation, and inhibition of cancer growth [J].
Chaudhari, Anita ;
Mahfouz, Magdy ;
Fialho, Arsenio M. ;
Yamada, Tohru ;
Granja, Ana Teresa ;
Zhu, Yonghua ;
Hashimoto, Wataru ;
Schlarb-Ridley, Beatrix ;
Cho, Wonhwa ;
Das Gupta, Tapas K. ;
Chakrabarty, Ananda M. .
BIOCHEMISTRY, 2007, 46 (07) :1799-1810
[6]
Das Gupta TK, 2012, US Patent, Patent No. [8,232,244, 8232244]
[7]
Azurin Modulates the Association of Mdm2 with p53: SPR Evidence from Interaction of the Full-Length Proteins [J].
Domenici, Fabio ;
Frasconi, Marco ;
Mazzei, Franco ;
D'Orazi, Gabriella ;
Bizzarri, Anna Rita ;
Cannistraro, Salvatore .
JOURNAL OF MOLECULAR RECOGNITION, 2011, 24 (04) :707-714
[8]
Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia [J].
Druker, BJ ;
Lydon, NB .
JOURNAL OF CLINICAL INVESTIGATION, 2000, 105 (01) :3-7
[9]
FIALHO AM, 2010, EMERGING CANC THERAP, P405
[10]
Fialho AM, 2012, ISRN NEUROL, V2012